Figure 4: Osteoclast-targeted antagomir-214-3p treatment rescues bone phenotype in OC-miR-214-3p mice.
From: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
(a) A schematic diagram illustrating the experimental design. The 4-week-old OC-miR-214-3p or WT mice were intravenously injected with PBS (OC214-3p/WT), (D-Asp)8-liposome (vehicle) alone (OC214-3p+Veh/WT+Veh), (D-Asp)8-liposome-antagomir nonsense control (OC214-3p+NC/WT+NC) and (D-Asp)8-liposome-antagomir-214-3p (OC214-3p+AMO/WT+AMO), respectively, at a weekly interval and killed 4 weeks after the first treatment. Another group of OC-miR-214-3p or WT mice were killed at 4-week-old before treatment initiation as baseline (OC214-3p-BS/WT-BS). (b) Representative micro-CT images of the distal femur metaphysis in each group. Scale bars, 1 mm. (c) The values of micro-CT parameter (BMD) at the distal femur metaphysis in each group. (d) Representative images of new bone formation assessed by double labelling with calcein green and xylenol orange at the distal femur metaphysis in each group. Scale bars, 10 μm. (e) The values of bone histomorphometry parameter (BFR/BS) at the distal femur metaphysis in each group. The n value for each group is indicated at the bottom of each histogram. All data are the mean±s.d. *P<0.05. NS, not significant. One-way ANOVA with a post-hoc test was performed.
